Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE vs ESTARYLLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Moderate to severe pain where an opioid analgesic is appropriate
FDA-approved: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.,Off-label: Acne vulgaris (for norgestimate-containing pills), management of menstrual disorders (e.g., dysmenorrhea, abnormal uterine bleeding), hormone therapy for transgender women (non-standardized).,Note: Off-label uses are not FDA-approved for this specific formulation.
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Ethinyl estradiol is primarily metabolized by CYP3A4, with conjugation to glucuronides and sulfates. Norgestimate is rapidly metabolized to its active metabolite, norelgestromin, and further to levonorgestrel; involvement of CYP2C19 and CYP3A4 in norgestimate metabolism is noted.
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Ethinyl estradiol: 97-98% bound to albumin, with minor binding to sex hormone-binding globulin
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Ethinyl estradiol: approximately 2.8 L/kg; indicates extensive tissue distribution
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
Oral: approximately 55% due to first-pass metabolism; consistent in healthy females
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment or end-stage renal disease due to lack of data.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; dose adjustment not specifically defined, but alternative contraception recommended.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
Approved for use in postmenarchal adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). No weight-based dosing required.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
Not indicated in postmenopausal women. No specific geriatric dosing; contraindicated in women over 60 years due to increased thromboembolic risk.
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptives. This risk increases with age (especially in women over 35 years of age) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Thrombotic disorders: Increased risk of venous thromboembolism (VTE) and arterial thromboembolism (e.g., MI, stroke). Discontinue if thrombotic event occurs.,Cardiovascular disease: Avoid in women with uncontrolled hypertension, diabetes with vascular involvement, or history of thromboembolic disease.,Cigarette smoking: Strongly advise cessation, especially in women over 35.,Liver disease: Discontinue if jaundice or cholestasis develops; contraindicated in acute viral hepatitis or severe cirrhosis.,Hormone-dependent malignancies: Increased risk of breast cancer (current use) and cervical cancer; avoid if known or suspected breast cancer.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate and lipid metabolism: Monitor glucose and lipids in predisposed patients; may impair glucose tolerance and increase triglycerides.,Headache: Evaluate if new-onset or worsening migraine, especially with focal neurological symptoms.,Uterine bleeding: Rule out pregnancy if amenorrhea occurs; irregular bleeding may require evaluation.,Depression: Monitor for mood changes; discontinue if severe depression recurs.,Angioedema: Risk in women with hereditary angioedema.
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Known or suspected pregnancy,Current or past venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism),Current or past arterial thrombosis (e.g., myocardial infarction, stroke) or prodromal conditions (e.g., angina, transient ischemic attack),Known thrombophilic disorders (e.g., Factor V Leiden, prothrombin mutation, antithrombin deficiency),History of cerebrovascular or coronary artery disease,Uncontrolled hypertension (sustained >160/100 mm Hg),Diabetes mellitus with nephropathy, retinopathy, neuropathy, or other vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura) in women over 35,Current or past breast cancer, or other estrogen- or progestin-sensitive cancer,Active liver disease (e.g., acute viral hepatitis, severe cirrhosis) or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component of Estarylla,Use of highly active antiretroviral therapy (HAART) containing ritonavir or direct-acting antivirals for hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir) due to potential for hepatotoxicity
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
There are no known significant food interactions. Grapefruit juice may increase estrogen levels but clinical significance is unclear; consider moderate intake.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations from inadvertent exposure, but increased risk of cardiovascular and limb defects in some studies. Second and third trimesters: Associated with fetal harm, including cardiovascular effects (e.g., congenital heart defects) and possible estrogenic effects, though data are limited. Postnatal effects: Potential long-term developmental effects unknown. Overall risk is low but not zero; avoid use in pregnancy.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
Estarylla is excreted in breast milk in small amounts (ethinyl estradiol: M/P ratio ~0.2; levonorgestrel: M/P ratio ~0.3-0.4). Combined hormonal contraceptives may reduce milk production and affect milk composition, especially in early postpartum. Use is generally not recommended until breastfeeding is well-established (at least 6 weeks postpartum). For later use, progestin-only methods are preferred. Monitor infant for jaundice and growth.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
Estarylla is contraindicated in pregnancy. No dosing adjustments are recommended because it should not be used. Pregnancy alters pharmacokinetics of oral contraceptives (e.g., increased volume of distribution, altered hepatic metabolism), but no dose changes are indicated due to contraindication. If inadvertently taken, discontinue immediately.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It is indicated for prevention of pregnancy. Monitor for thromboembolic events, especially in smokers over 35. Counsel on missed dose management: take as soon as remembered, use backup contraception if more than 24 hours late. May reduce menstrual cramps and acne. Not recommended in patients with history of estrogen-dependent neoplasia, liver disease, or uncontrolled hypertension.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
Take one pill daily at the same time each day.,If you miss a pill, take it as soon as remembered; use backup contraception if more than 24 hours late.,Do not smoke while taking this medication, especially if over 35.,Report any signs of blood clots: leg pain, chest pain, shortness of breath, or sudden vision changes.,This medication does not protect against HIV or other STDs.
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE vs ESTARYLLA, answered by our medical review team.
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. ESTARYLLA is a Combined Oral Contraceptive that works by Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE and ESTARYLLA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. The standard adult dose of ESTARYLLA is: One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE and ESTARYLLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. ESTARYLLA is classified as Category C. Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.